Sign In
Buy SYRS
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know
11:22am, Tuesday, 16'th Jan 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 199.3% in Syros Pharmaceuticals, Inc. (SYRS). While the effectiveness of this highly sought-after metric is que
Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick
10:34am, Thursday, 11'th Jan 2024
Syros Pharmaceuticals (SYRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here's What Insiders Are Buying to Wrap Up the Year
10:10am, Sunday, 31'st Dec 2023
As the year wound to a close, biotechs were in focus among the notable insider purchases.
Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene
11:17am, Thursday, 07'th Dec 2023
Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
04:17pm, Sunday, 03'rd Dec 2023
If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clar
Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript
01:53pm, Tuesday, 14'th Nov 2023
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations & Corporate Communications N
Syros Pharmaceuticals undergoes leadership shakeup, workforce reduction
04:09pm, Monday, 02'nd Oct 2023
Syros Pharmaceuticals shares dropped on Monday after a series of shakeups at the biotech company. The firm is saying goodbye to its CEO, Nancy Simonian, who will retire by the end of the year, and chi
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
10:40am, Tuesday, 08'th Aug 2023
Syros Pharmaceuticals, Inc. (SYRS) came out with a quarterly loss of $1.30 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $5.40 per share a year ago.
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
07:30am, Tuesday, 01'st Aug 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies
Pfizer to end license deal with Syros for blood disorder therapies
05:46pm, Friday, 21'st Jul 2023
Syros Pharmaceuticals said on Friday Pfizer will terminate a license deal between the companies related to the development of novel therapies for two blood disorders.
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
07:30am, Thursday, 08'th Jun 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
07:30am, Wednesday, 03'rd May 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates
11:18am, Thursday, 02'nd Mar 2023
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t
Syros: Multiple Shots On Goal In Blood Cancer Space
10:10am, Wednesday, 08'th Feb 2023
Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene overexpression, expected Q3 of 2024. The global m
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?
11:18am, Wednesday, 01'st Feb 2023
Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe
